Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy in Sanfilippo Syndrome Type B
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B
Tartisan Nickel Corp. Appoints Jack Jacobs, Congressional Medal of Honour Recipient, Retired Army Colonel and Distinguished Business Executive to Board of Advisors
